The Phase 2 GATEWAY trial demonstrates that zodasiran, an RNAi therapeutic targeting ANGPTL3, significantly reduces LDL cholesterol in patients with homozygous familial hypercholesterolaemia (HoFH) by approximately 36-40%. The treatment was well-tolerated and showed sustained efficacy, offering a promising LDLR-independent therapeutic avenue for this high-risk population.